PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
125.64%
Net income growth at 50-75% of VET's 199.45%. Martin Whitman would worry about lagging competitiveness unless expansions are planned.
5.16%
Less D&A growth vs. VET's 15.22%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
7.46%
Lower deferred tax growth vs. VET's 80.64%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
No Data
No Data available this quarter, please select a different quarter.
61.49%
Slight usage while VET is negative at -280.47%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
61.49%
Growth of 61.49% while VET is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
-129.91%
Both negative yoy, with VET at -184.74%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
52.13%
Some CFO growth while VET is negative at -51.09%. John Neff would note a short-term liquidity lead over the competitor.
12.91%
Lower CapEx growth vs. VET's 45.67%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
-182.44%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
131.88%
Purchases growth of 131.88% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-12.91%
We reduce yoy sales while VET is 462.58%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
3.41%
We have some outflow growth while VET is negative at -246.54%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
1.11%
Investing outflow well above VET's 1.66%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
4.08%
Debt repayment growth of 4.08% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-100.00%
Negative yoy issuance while VET is 8.54%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.